Xstim

Executive Summary

Xstim is a privately held medical device company headquartered in San Diego, California, focused on advancing spine fusion outcomes through its proprietary electrical stimulation therapy. Founded in 2015, the company has achieved regulatory approval for its Xstim Spine Fusion Stimulation Therapy, which leverages targeted electrical stimulation to harness the body's natural healing processes and promote successful spinal fusion. The technology addresses a critical need in the orthopedic and neurosurgery markets, where non-union or delayed fusion remains a significant challenge. With an approved product and a clear value proposition in a multi-billion-dollar market, Xstim is positioned to capture share among spine surgeons and hospitals seeking to improve fusion rates and reduce revision surgeries. The company's stage as 'Approved' indicates it has cleared key regulatory hurdles, yet limited public information suggests it may be in early commercialization or seeking strategic partnerships to scale. Given the strong clinical rationale and unmet need, Xstim represents a promising opportunity in the neurostimulation and medical device space, although near-term visibility into revenue and market penetration remains low.

Upcoming Catalysts (preview)

• Q4 2026Commercial Launch or Partnership Announcement60% success
• Q1 2027Clinical Study Publication on Fusion Success Rates70% success
• Q2 2027Reimbursement Code Expansion or Coverage Decision50% success